Drug Trial Radar · NCT03579966
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Last checked: Nov 20, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
63
Actual
Start
Jun 11, 2018
Primary completion
Aug 5, 2022
Study completion Aug 5, 2022
Sponsor
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
Conditions
- Myasthenia Gravis, MuSK
- AChR Myasthenia Gravis
Interventions
Amifampridine PhosphateDrug
tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: over 39 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Univerity of Pennsylvania
Philadelphia, Pennsylvania
Department of Neuroimmunology and Neuromuscular Diseases Carlo Besta Neurological Institute Via Celoria
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.